Hypertonic saline reduces neutrophil-epithelial interactions in vitro and gut tissue damage in a mouse model of colitis

Tillinger, Wolfgang; McCole, Declan F.; Keely, Stephen J.; Bertelsen, Lone S.; Wolf, Paul L.; Junger, Wolfgang G.; Barrett, Kim E.

doi:10.1152/ajpregu.00412.2007

Cited by 7 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tillinger et al investigated HS treatment of neutrophils in vitro . They noted a dose-dependent effect involving decreased cell migration and the disruption of T84 monolayers compared with untreated control cells ( 82 ). Compared with physiological saline, Oreopoulos et al found inhibition of ischemia/reperfusion-induced hepatic expression of ICAM-1 mRNA with HS from in vivo model of hepatic ischemia-reperfusion and in vitro model from the activated endothelial cell.…”

Section: Discussionmentioning

confidence: 99%

Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy

Gennari-Felipe

Borges²,

Dermargos³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) features hyper-inflammation, cytokine storm, neutrophil function changes, and sodium chloride (NaCl) homeostasis disruption, while the treatment with NaCl hypertonic solutions (HS) controls electrolytic body homeostasis and cell functions. HS treatment is a simple, popular, economic, and feasible therapy to regulate leukocyte function with a robust anti-inflammatory effect in many inflammatory diseases. The purpose of this narrative review is to highlight the knowledge on the use of HS approaches against viral infection over the past years and to describe the mechanisms involved in the release of neutrophil extracellular traps (NETs) and production of cytokine in severe lung diseases, such as COVID-19. We reported the consequences of hyponatremia in COVID-19 patients, and the immunomodulatory effects of HS, either in vitro or in vivo. We also described the relationship between electrolyte disturbances and COVID-19 infection. Although there is still a lack of clinical trials, hypertonic NaCl solutions have marked effects on neutrophil function and NETs formation, emerging as a promising adjuvant therapy in COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy

Gennari-Felipe

Borges²,

Dermargos³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Administration of 1 mL of 0.9% NaCl corresponds with a dose of approximately 40 mL/kg of NaCl solution, which according to previous reports is considered hypertonic when given in a single injection [46]. Hypertonic saline solutions were previously shown to improve the DAI in DSS-treated mice, which was associated with reduced inflammation on day 7 [46]. In our hands, fluid supplementation had no effects on any parameter associated with inflammation on day 7 suggesting that epithelial restitution occurred during the phase of recovery.…”

Section: Discussionmentioning

confidence: 99%

Fluid supplementation accelerates epithelial repair during chemical colitis

et al. 2019

View full text Add to dashboard Cite

The dextran sulfate sodium (DSS) model of colitis is a common animal model of inflammatory bowel disease that causes pain and distress. In this study, we aimed to determine whether fluid supplementation can be used as a welfare-based intervention to minimize animal suffering. C57Bl/6 females undergoing acute colitis by administration of 3% DSS in drinking water were supplemented with 1 mL intraperitoneal injections of NaCl and compared to non-supplemented control mice. Mouse behavior and locomotive activity were assessed on days 5–6 after DSS initiation by means of tail suspension, novel object recognition and open field activity tests. Mice were euthanized after either the acute (day 7) or the recovery phase (day 12) of colitis and inflammation, epithelial proliferation, and differentiation were assessed by means of histology, immunohistochemistry, quantitative PCR, and western blot. We found that fluid-supplemented mice had reduced signs of colitis with no alterations in behavior or locomotive activity. Furthermore, we observed an accelerated epithelial repair response after fluid hydration during the acute phase of colitis, characterized by increased crypt proliferation, activation of ERK1/2, and modulation of TGF-β1 expression. Consistent with these findings, fluid-supplemented mice had increased numbers of goblet cells, upregulated expression of differentiation markers for absorptive enterocytes, and reduced inflammation during the recovery phase. Our results show that fluid hydration does not reduce stress in DSS-treated mice but alters colitis evolution by reducing clinical signs and accelerating epithelial repair. These results argue against the routine use of fluid supplementation in DSS-treated mice.

show abstract

Sleep patterns, genetic susceptibility, and digestive diseases: a large-scale longitudinal cohort study

Ma,

Yu,

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

Background: Sleep problems are prevalent. However, the impact of sleep patterns on digestive diseases remains uncertain. Moreover, the interaction between sleep patterns and genetic predisposition with digestive diseases has not been comprehensively explored. Methods: 410,586 participants from UK Biobank with complete sleep information were included in the analysis. Sleep patterns were measured by sleep scores as the primary exposure, based on five healthy sleep behaviors. Individual sleep behaviors were secondary exposures. Genetic risk of the digestive diseases was characterized by polygenic risk score. Primary outcome was incidence of 16 digestive diseases. Results: Healthy sleep scores showed dose-response associations with reduced risks of digestive diseases. Compared to participants scoring 0-1, those scoring 5 showed a 28% reduced risk of any digestive disease, including a 50% decrease in irritable bowel syndrome, 37% in non-alcoholic fatty liver disease, 35% in peptic ulcer, 34% in dyspepsia, 32% in gastroesophageal reflux disease, 28% in constipation, 25% in diverticulosis, 24% in severe liver disease, and 18% in gallbladder disease, whereas no correlation was observed with inflammatory bowel disease and pancreatic disease. Participants with poor sleep and high genetic risk exhibited approximately a 60% increase in the risk of digestive diseases. A healthy sleep pattern is linked to lower digestive disease risk in participants of all genetic risk levels. Conclusions: In this large population-based cohort, a healthy sleep pattern was associated with reduced risk of digestive diseases, regardless of the genetic susceptibility. Our findings underscore the potential impact of healthy sleep traits in mitigating the risk of digestive diseases.

show abstract

Hypertonic saline reduces neutrophil-epithelial interactions in vitro and gut tissue damage in a mouse model of colitis

Cited by 7 publications

References 32 publications

Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy

Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy

Fluid supplementation accelerates epithelial repair during chemical colitis

Sleep patterns, genetic susceptibility, and digestive diseases: a large-scale longitudinal cohort study

Contact Info

Product

Resources

About